Abstract
Introduction
Disease management has become a common term in the U.S. health care system.
Yet, the more widely the term has been adopted, the more diffuse the defi
nition of this health care strategy has become. Whatever the actual defi
nition, many employers regard cost-containment as a key objective of DM
initiatives. DM activity is focused largely on several highly prevalent
chronic disorders-diabetes, asthma, hypertension, and dyslipidemia.
Manufacturers of therapies need to prepare for the impact of DM on these
markets.
Get the Answers You Need to Shape Your Strategy
- A 2006 survey found that 76% of employers saw a connection between
employees' health status and employees' productivity. How can
pharmaceutical companies underscore the positive impact of good health on
productivity?
- The most basic challenge in recruiting participants for any form of care
management program is identifying suitable candidates for enrollment. How
do health plans stratify patients into risk categories? How do they use this
information to project health care costs for patients?
- Disease management programs will likely alter established prescribing
patterns. What effects will these programs have on drug sales? Which
classes will be most affected?
- For most employers, cost-containment is an essential objective of care
management. How do companies rate the effectiveness of these plans as a
cost-cutting measure?
Scope
- Disease management overview: defi nition and evolution of disease
management and related strategies.
- Employers' views on disease management: fi ndings from an employer
health benefi t survey.
- Challenges of patient enrollment: identifying candidates,
persuading members to sign up for the program, whether to offer incentives to
employees.
- Disease management in Medicare: how to apply the DM concept to
Medicare benefi ciaries.
- State initiative: several state governments have begun to explore
the potential of DM.
- Outlook: implications of disease management for the pharmaceutical
industry.
| 
View Cart
